Fol News

Tutti gli approfondimenti
Tutte le notizie

Repros Therapeutics Inc. [Nasdaq:RPRX]

Ciao Cla..... , io oggi ho incrementato AIG (poche) , tu come la vedi la situazione?
 
dici che torneremo ai vecchie 0,80
 
sei uscito vincent vero
 
Nessuno ha piu' fatto nulla?:cool:
 
4,35$ meno...meno...non so piu' quanto meno faccia oggi:eek::mad::D
 
Sempre peggio:mad::eek:
Continua a segnare minini.
Non si ferma piu'

MAMMAAAAAAAAA:'(:angry::wall::eek::mad:
 
Dovrebbe fermarsi la valanga a 2,99-3,02;)
 
guerriero72 ha scritto:
:no::no::no:...-15% e close a 2,55,dopo il -40% di ieri..neanche avesse fallito una fase 3...:rolleyes:comunque preso 1° cip a 2,46...:)
Clicca per espandere...
QUESTA E' QUASI ANDATA:mad::eek::wall:


UPDATE 2-Repros: adverse effects of Proellex not yet resolved
Thu Jul 23, 2009 4:33pm EDT Email | Print | Share| Reprints | Single Page[-] Text [+]

Market News
Nasdaq snaps 12-day run; Dow, S&P 500 edge up | Video
CIT courts creditors, plans large debt exchange
Oil rises above $68 on economic optimism | Video
More Business & Investing News... * 4 patients still under close watch

* Shares fall to their four-year low (Adds details, more analyst' comments, updates share movement)

BANGALORE, July 23 (Reuters) - Repros Therapeutics Inc (RPRX.O) said it was yet to resolve the adverse effect caused by elevated levels of liver enzymes in four patients, who were treated with the company's experimental drug for uterine fibroids.

Shares of the company closed down nearly 40 percent at $2.99 Thursday on Nasdaq. They hit a four-year low of $2.94 earlier in the day.

Repros also said that all four patients were kept under close watch.

However, on July 7, the company had said all the adverse events that occurred in the first four months of the treatment, which involved nine people, were resolved without intervention upon discontinuation of the product.

:bye:
 
Claudiano ha scritto:
QUESTA E' QUASI ANDATA:mad::eek::wall:


UPDATE 2-Repros: adverse effects of Proellex not yet resolved
Thu Jul 23, 2009 4:33pm EDT Email | Print | Share| Reprints | Single Page[-] Text [+]

Market News
Nasdaq snaps 12-day run; Dow, S&P 500 edge up | Video
CIT courts creditors, plans large debt exchange
Oil rises above $68 on economic optimism | Video
More Business & Investing News... * 4 patients still under close watch

* Shares fall to their four-year low (Adds details, more analyst' comments, updates share movement)

BANGALORE, July 23 (Reuters) - Repros Therapeutics Inc (RPRX.O) said it was yet to resolve the adverse effect caused by elevated levels of liver enzymes in four patients, who were treated with the company's experimental drug for uterine fibroids.

Shares of the company closed down nearly 40 percent at $2.99 Thursday on Nasdaq. They hit a four-year low of $2.94 earlier in the day.

Repros also said that all four patients were kept under close watch.

However, on July 7, the company had said all the adverse events that occurred in the first four months of the treatment, which involved nine people, were resolved without intervention upon discontinuation of the product.

:bye:
Clicca per espandere...

o non hai approfondito perche' non ti interessa..o sei molto superficiale caro claudio...:rolleyes::yes:il farmaco da' dei risultati,ma meglio o peggio, dipende dai dosaggi...e' la dose di 50mg che ha deluso..non il farmaco in toto..http://biz.yahoo.com/bw/090723/20090723005355.html?.v=1 ....qui, come ho detto sopra,con un -60% in 2 giorni sembra sia fallito un farmaco in fase 3...niente di cio',molto esagerato il ribasso...e poi io sono gia' sposato:cool:,ho preso un primo cip e se scende incremento..ma per prendere come con MTXX, un bel rimbalzo, su stress da vendite non molto chiare e da panico..:yes:
 
Devi accedere o registrarti per poter rispondere.
Indietro